Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Glioblastoma Awareness Day, is dedicated to raising awareness for the most common and deadliest type of brain cancer. At $CADL, we’re developing our viral immunotherapy candidate, CAN-3110, as a potential treatment for glioblastoma.
https://bit.ly/3Y84GbL
Nice to see @CandelTx in the top 6 here, @paulpetertak 👏🏼👊🏻
Wishing everyone a fun and safe 4th of July holiday. Happy Independence Day!
#IndependenceDay #4thofJuly
The third (in humans) is to vaccinate the patient against the variety of antigens specific for the patient’s tumor: in a small randomized clinical trial in borderline resectable pancreatic cancer, at 24 months, a survival rate of 71.4% was observed in CAN-2409 treated patients,
